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Abstract
Background: The cell cycle plays a key role in human health and disease, including development and cancer. The
ability to easily and reversibly control the mammalian cell cycle could mean improved cellular reprogramming, better
tools for studying cancer, more efficient gene therapy, and improved heterologous protein production for medical or
industrial applications.
Results: We engineered RNA-based control devices to provide specific and modular control of gene expression in
response to exogenous inputs in living cells. Specifically, we identified key regulatory nodes that arrest U2-OS cells in
the G0/1 or G2/M phases of the cycle. We then optimized the most promising key regulators and showed that, when
these optimized regulators are placed under the control of a ribozyme switch, we can inducibly and reversibly arrest
up to ~80 % of a cellular population in a chosen phase of the cell cycle. Characterization of the reliability of the final
cell cycle controllers revealed that the G0/1 control device functions reproducibly over multiple experiments over
several weeks.
Conclusions: To our knowledge, this is the first time synthetic RNA devices have been used to control the mammalian
cell cycle. This RNA platform represents a general class of synthetic biology tools for modular, dynamic, and multi-output
control over mammalian cells.
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Background
Synthetic biology aims to make cells reliably programmable
by applying engineering principles to the design of genetic
circuits to control and monitor cellular behavior [1–7].
One approach to engineering genetic circuits leverages
existing cellular networks and interfaces synthetic control
systems at key nodes in these networks to rewire signal
processing and cellular decision making [8, 9]. In addition,
recent advances in the field are leading to genetic circuits
of higher-order complexity in mammalian cells [10–14],
which may ultimately be used to engineer human cells for
sensing conditions in the body, producing drugs or useful
materials, or addressing disorders of sophisticated pheno-
types, such as those linked to cell cycle and differentiation.
Cell cycle, in particular, plays a key role in human health
and disease, including development and cancer [15]. Cell
cycle processes produce dramatic changes in cell physi-
ology, but are often ignored in studies. The creation of
model human cell lines that can be easily and reversibly
paused at specific cell cycle phases can be used to further
cancer research, cell cycle research, and biotechnology in
general. For example, heterologous protein production for
industrial or medical applications is likely more efficient
during G0/1 and G2, when fewer resources are dedicated
to division [16]. In addition, signal processing in the self-
renewal versus differentiation decision is potentially linked
to the length of certain phases of the cell cycle [17]. Thus,
better understanding and control over cell cycle progres-
sion may aid in more effective cell re-programming [17].
Further, tools for genetic manipulation in mammalian
cells are typically too inefficient for viable gene therapy
and limit current research. Studies have shown that hom-
ologous recombination is more active in S and G2 phases,
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both of which are relatively short in a normal cell cycle
[18]. Thus, the ability to pause cells in S and G2 has
the potential to increase the reliability of mammalian
genetic integration techniques. In addition, cells tem-
porarily paused in G1 have been shown to stably ex-
press transgenes from episomes, which may provide a
strategy for gene therapy that does not rely on disrupt-
ing the genome [19].
Current methods for altering cell cycle progression
rely on small molecule inhibitors or nutrient deprivation
methods [20]. While effective, these approaches can
present a number of drawbacks, including exhibiting
specificity to a particular cell type, being broadly disrup-
tive of cellular processes, and being limited in capacity
to extend to different networks due to lack of genetic
encoding. A genetically encoded system supporting con-
trol over cell cycle progression has the potential to ad-
dress limitations with existing chemical approaches.
Such a synthetic biology-based approach relies on (i) the
identification of key regulatory nodes in native cell cycle
networks and (ii) the integration of tailorable gene-
control devices that can modulate the activities of these
nodes in response to user-specified signals.
RNA-based gene-control devices are a class of gene-
regulatory elements that have been used in microbes to
humans cells for diverse cellular applications [6, 8, 12,
21–25]. Ribozyme-based gene-control devices are self-
cleaving RNA regulatory elements [26], where cleavage
can result in transcript degradation when placed in the
3′-untranslated region (3′ UTR) of the target gene of
interest. Ribozyme devices generally couple an RNA
aptamer [27, 28] to the ribozyme element such that lig-
and binding to the aptamer affects the cleavage activity
of the ribozyme. Thus, ribozyme devices can function as
ligand-responsive genetic switches or ribozyme switches,
where ribozyme activity, and thus target RNA and protein
levels, are modulated as a function of ligand concentration
in the cell [29]. Ribozyme switches can be efficiently devel-
oped through computational or high-throughput screening
methods [29–31], where switches prototyped in microbial
systems can be readily transferred to mammalian systems
with predictable results [32]. Small molecule-responsive
ribozyme switches have been used to achieve drug-
modulated control over complex phenotypes in mamma-
lian cells, including viral replication [22, 33] and T-cell
survival and proliferation [12].
Here, we demonstrate ribozyme switches that control
the arrest of human cells in various phases of the cell
cycle. Specifically, we identified key regulatory nodes
that induce arrest of cells in G0/1 or G2/M phases of
the cycle and tune the expression of the most promis-
ing key regulators to optimize the arrest phenotype. We
coupled theophylline-responsive ribozyme switches to
the identified key regulatory nodes and demonstrated
drug-responsive control over cell cycle arrest in G0/1 or
G2/M. These genetic cell cycle controllers are able to
inducibly and reversibly arrest up to ~80 % of a popula-
tion of cells in a chosen phase of the cell cycle and per-
form reliably over multiple experiments over a time frame
of several weeks. More broadly, ligand-responsive RNAs
represent a class of synthetic biology tools that are both
genetically encoded and capable of regulating intracellular
protein levels in response to user-specified molecular sig-
nals, and can be adapted for sophisticated control of com-
plex processes in human cells.
Results and discussion
Identifying key regulatory nodes that arrest cells in G0/1
The human cell cycle is a complex sequence of carefully
timed activities that ensures proper genome replication
and cell division/segregation. The signaling networks con-
trolling cell progression between the different phases are
multi-component systems and interwoven with other pro-
cesses in the cell to safeguard genomic integrity through
divisions. Despite decades of research, our understanding
of the underlying networks and processes in the cell cycle
remains incomplete. One trend that emerges from the
body of prior work in this field is that despite the large
number of genes involved in each cell cycle transition, in
practice, a very small set of key protein regulators function
as nodes. The regulatory nodes act such that changes in
the expression level of that node results in measurable
population level changes in cell cycle progression.
Previous studies have demonstrated the existence of such
regulatory nodes and have used these nodes to investigate
the biochemical mechanism of the cell cycle [34, 35]. How-
ever, it is unclear to what degree a single key node is able
to control cell cycle (in terms of percentage of cells in a
population that respond). It is also unclear to what degree
an overexpressed key node is able to overcome the large
amount of transcriptional and posttranslational regulation
that the protein is under through control systems endogen-
ous to the cell. A truly effective node may need to elimin-
ate some of the sites of regulation in the protein to better
direct the control of cell cycle without being disabled by
the endogenous programs.
We set out to identify key regulatory nodes for inhibit-
ing progression of G0/1 to S in mammalian cells and to
determine the degree of inhibition associated with this
genetic regulatory strategy. The cDNAs for a panel of pu-
tative regulatory node proteins were overexpressed from a
mammalian expression plasmid in U2-OS cells by transi-
ently co-transfecting 3–3.75 μg of the individual plasmids
encoding the expression of these candidate proteins with
1.13-1.5 μg of a plasmid encoding a GFP reporter for use
as a transfection marker for a total of 4.5 μg transfected
DNA per sample. The panel of proteins screened was
comprised of candidates most likely to exhibit the desired
Wei and Smolke Journal of Biological Engineering  (2015) 9:21 Page 2 of 13
activity based on a review of the literature and represented
a sampling of non-modified proteins as well as modified
proteins, designed to eliminate some aspect of endogen-
ous regulation (Additional file 1: Table S1). Cells across
the cell cycle phases from each sample were assayed three
days after transfection via DNA staining with propidium
iodide followed by quantification using flow cytometry
(Additional file 1: Figure S1-S2). These assay conditions
were selected to allow reliable quantification of a sufficient
number of cells per sample and supported rapid screening
for regulatory nodes that are promising for further investi-
gation. A plasmid encoding the expression of a fluorescent
protein (mCherry) served as a negative control that does
not alter cell cycle progression.
The data from the screening assay indicate three regula-
tory nodes for inducing a G0/1 arrested state in U2-OS
cells - p16 (~60 % in G0/1), p21 (~71 % in G0/1), and p27
(~71 % in G0/1) (Fig. 1a, b). The unmodified cell cycle
program (i.e., mCherry expression) results in ~50 % of
cells in G0/1 under the same conditions. Compared to
using double thymidine block, a commonly used small
molecule based method for arresting cells in G0/1 and
early S phase, which arrests approximately 86-95 % of cells
(Additional file 1: Figure S3) [36], the identified regulatory
nodes are less effective, but still represent an appreciable
amount of modification of the cell cycle (Additional file 1:
Figure S3). Thus, a single protein in a complex network,
which contains at least 142 proteins directly annotated by
the Gene Ontology project as being involved in the “G1/S
transition of mitotic cell cycle” in Homo sapiens (or ~0.7 %
of the network), controlled up to 42 % of the cells that
were previously escaping G0/1 arrest (AmiGO 2.2.0) [37].
No modifications to the identified regulatory node proteins
were necessary for their activity in inhibiting cell cycle pro-
gression. It is of note that these conclusions are specific to
U2-OS cells at three days after transfection and not neces-
sarily generalizable to other cell lines or other time points
in a transient transfection assay.
The identification of p16, p21, and p27 as key regulators
of the G0/1 to S transition is supported by their roles in
the cell cycle network (Fig. 1a). Specifically, p16 (INK4a)
is a well-studied inhibitor of Cdk4 and Cdk6, which are
important regulators of interphase. U2-OS cells, which are
deficient in p16, should be particularly sensitive to overex-
pression of this protein [34]. p21 (Cip1/Waf1) and p27
(Kip1) are members of the general Cip/Kip family of
Fig. 1 Screen to identify key regulatory nodes that produce cell cycle arrest in G0/1 and G2/M. a Schematic of the progression through the
phases of cell cycle and a simplified representation of the identified key node function in cell cycle regulation. b, c Potential regulatory node
proteins were overexpressed and the resulting cell populations were assayed for changes in the percentage of cells that were in G0/1 phase
(b) or G2/M phase (c) relative to a negative control (i.e., control plasmid that does not alter cell cycle progression). *, p < 0.05. Cells were
transiently co-transfected with 3–3.75 μg of the plasmids encoding the expression of these candidate proteins and 1.13–1.5 μg of a plasmid
encoding a GFP reporter. Error bars represent standard deviation across biological triplicates
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proteins, which promote assembly and thus activation of
the cyclin D-Cdk4,6 complexes that control interphase,
but inhibit the downstream cyclin-Cdk2 complexes that
control the G1 to S transition and early S phase. All three
of these node proteins are interdependent, as increases in
cyclin D activates Cdk4,6 and sequesters Cip/Kip from
downstream cyclin-Cdk2, which also stimulates division.
Meanwhile, increased levels of p16 disassembles cyclin D-
Cdk4,6, releasing Cip/Kip to bind cyclin-Cdk2, thereby ar-
resting cells in G0/1 [38].
The screening assay also provided some unexpected
results. For example, the overexpression of pRb and
mutant forms of pRb, such as pRb(ΔCDK)HA and
pRB(T821, 826A), which remove regulation by Cdk and
inhibitory phosphorylation sites, respectively, [34, 39]
did not lead to appreciable arrest in G0/1 (Fig. 1b).
These results are surprising as pRb is an important in-
hibitor of the E2F-dependent gene expression cascade
that triggers the transition of G1 to S, and heterologous
expression of pRB(ΔCDK)HA was previously shown to
significantly arrest U2-OS cells in G0/1 [34]. Taken to-
gether, our results highlight that functional screens
within the desired cell system are important for identi-
fying effective regulatory nodes of complex networks
controlling sophisticated cellular phenotypes.
Identifying key regulatory nodes that arrest cells in G2/M
Based on our success in identifying key regulatory nodes
for inhibiting progression of the G0/1 to S transition, we
applied a similar screening strategy to identify key regula-
tory nodes for inhibiting progression of the G2/M to G0/1
transition. A panel of putative regulatory node proteins
for the G2/M to G0/1 transition were identified based
on a review of the literature for most likely candidates
(Additional file 1: Table S1). The cDNAs for these
candidate proteins were overexpressed from a mammalian
expression plasmid in U2-OS cells by transiently co-
transfecting 3–3.75 μg of the individual plasmids encoding
the expression of these candidate proteins with 1.13-
1.5 μg of a plasmid encoding a GFP reporter for use as a
transfection marker for a total of 4.5 μg transfected DNA
per sample. The distribution of cells across the cell cycle
phases for each sample was quantified via DNA staining
using similar assay conditions as previously described.
The data from the screening assay indicate a single
regulatory node for inducing a G2/M arrested cell state in
U2-OS cells - cyclinB1mut (CCNB1m) (~44 % in G2/M)
(Fig. 1c). The negative control (i.e., cells harboring a plas-
mid encoding DsRed expression) results in ~26 % of cells
in G2/M under the same conditions. Thus, overexpression
of the key node cyclinB1mut (CCNB1m) results in ~70 %
more cells in G2/M. For the G2/M transition to G0/1, a
single protein in a large network, which contains at least
131 proteins annotated as “G2/M transition of mitotic cell
cycle” by the Gene Ontology project (or ~0.8 % of the net-
work), was able to significantly increase the percentage of
cells in G2/M (AmiGO 2.2.0) [37]. It is of note that only a
mutant form (L45A, R42A) of cyclin B1 [40], which is less
susceptible to degradation, had an effect on cell cycle pro-
gression, while wild-type cyclin B1 and the closely related
cyclin B2 had no significant effect. It is of note that these
conclusions are specific to U2-OS cells at three days after
transfection and not necessarily generalizable to other cell
lines or other time points in a transient transfection assay.
The identification of the cyclinB1mut as a key regulator
of the G2/M to G0/1 transition is supported by its role in
the cell cycle network (Fig. 1a). The cyclin B-Cdk1 com-
plex activates the anaphase-promoting complex (APC) in
early mitosis and is subsequently destroyed by APC in late
mitosis. Destruction of the cyclin B-Cdk1 complex is ne-
cessary to transition out of mitosis, and thus a non-
degradable cyclin B would be expected to induce arrest in
M phase. Our observation that overexpression of wild-
type cyclin B does not induce measurable arrest in G2/M
(Fig. 1c) indicates that the amount of overexpression
achieved under the assay conditions is insufficient to over-
whelm the capability of APC. It was unexpected that the
overexpression of several of the other candidate proteins
did not lead to arrest in G2/M. For example, Emi1 was
not identified as a key regulatory node of G2/M in this
screen (Fig. 1c). Emi1 inhibits Cdc20, and activated
APC(Cdc20) is necessary for the metaphase to anaphase
transition in mitosis. Thus, overexpression of Emi1 was
expected to result in an increased percentage of cells in S
and G2/M [35].
Taken together, the results of our screening assays in-
dicate that it was possible to identify key regulatory pro-
tein nodes whose overexpression produces modulation
of the population level distribution of cells in G0/1 and
G2/M despite the extensive network of proteins involved
in controlling cell cycle phases.
Optimizing arrest phenotypes by tuning expression of
cell cycle regulatory nodes
We set out to determine methods for optimizing the
amount of cell cycle arrest that can be achieved. Previous
studies have demonstrated that simultaneously expressing
multiple regulatory nodes produced increased arrest com-
pared to individual expression of the nodes [34]. Thus, we
examined the effects of combined overexpression of mul-
tiple nodes. In addition, genome-wide analyses of cell
cycle phenotypes have reported large differences in the
regulators identified across cell types [41, 42]. Thus, we
examined the importance of cell type on the effectiveness
of identified regulators. Previous work has shown that the
arrangement of multiple expression cassettes within and
across plasmids can impact expression [43]. In particular,
the placement of two expression cassettes in tandem on
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the same plasmid can dampen expression of one or both
genes [44–47], while the placement of two expression cas-
settes across two different plasmids can result in hetero-
geneity between cells [43]. Thus, we examined whether
key regulatory node expression is more effective in cell
cycle arrest when co-expressed with a GFP reporter as
tandem expression cassettes on the same plasmid or sep-
arate cassettes across two plasmids.
We identified multiple key nodes that inhibit the G0/1
to S transition, and thus we tested whether overexpress-
ing these nodes in combination would improve arrest in
G0/1. The three most promising candidates for arrest in
G0/1 - p16, p21, and p27 - all regulate cell cycle through
Cdk4 and Cdk6, and therefore would be expected to
function synergistically. Plasmids encoding each of the
proteins separately were transiently transfected singly or
in combination at equal ratios into U2-OS cells and the
percentage of cells in each stage of the cell cycle was
measured as described previously. Under the assay con-
ditions, combinations of the G0/1 regulatory nodes did
not improve the amount of G0/1 arrest relative to the
level of arrest observed from overexpression of a single
key regulator (Fig. 2a). This result was unexpected as
RNAi knockdown of Cdk4 and Cdk6 together results in
more cells arrested in G0/1 compared to cell popula-
tions in which each Cdk was knocked down individually
(Additional file 1: Figure S4). However, the mechanism
of inactivation of Cdk4 and Cdk6 by p16, p21, and p27
is different, and perhaps less complete when compared
to direct silencing via RNAi.
In order to investigate the impact of cell type on the
ability of the identified regulatory nodes to arrest the cell
cycle, we selected HeLa and HEK293 as representative
commonly used cell lines and p16 as a representative key
Fig. 2 Impact of experimental parameters on the activity of regulatory nodes for cell cycle control. a Impact of combinatorial expression of key
regulatory nodes on cell cycle arrest in G0/1. U2-OS cells were transiently co-transfected with plasmids encoding overexpression of combinations
of one, two, and three key node proteins. The resulting arrest in G0/1 of the cell population was assayed via DNA staining and flow cytometry. b
Impact of p16 on cell cycle arrest in G0/1 of different cell lines. HeLa, HEK293, or U2-OS cells were transiently transfected with a plasmid encoding
p16 or a control and the percentage of the cell population in G0/1 was measured. c Impact of the arrangement of expression cassettes encoding
regulatory nodes on cell cycle arrest in G0/1. U2-OS cells were transiently transfected with a single plasmid containing two expression cassettes,
encoding a transfection marker and a regulatory node (p16 or p27) in tandem, or with two plasmids separately encoding the transfection marker
and the regulatory node. The resulting arrest in G0/1 of the cell population was assayed. *, p < 0.05. Error bars represent standard deviation across
biological triplicates
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regulator of the G0/1 to S transition. Each cell line was
transiently transfected with a plasmid encoding the ex-
pression of p16 or a negative control plasmid encoding
the expression of a GFP reporter and cell cycle was mea-
sured after three days. The data shows that overexpression
of p16 does not perturb the cell cycle relative to the nega-
tive control in HeLa cells, while overexpression of p16 de-
creases the percentage of cells in G0/1 slightly from 51 %
in the control samples to 45 % in the experimental sam-
ples in HEK293 cells (Fig. 2b). U2-OS cells, but not HeLa
or HEK293 cells, are expected to be especially sensitive to
p16 overexpression because they are deficient in p16 [34].
Our results highlight that functional screens used to iden-
tify key regulatory nodes in the cell cycle network may
identify candidates that are cell line dependent based on
the underlying network in that cell line. Thus, conducting
the screen in a cell line of interest is important for estab-
lishing an active system when engineering sophisticated
cellular phenotypes.
We next investigated whether the expression of the
key regulatory node protein is more effective in arresting
cells in the cell cycle when co-expressed with a reporter
protein as tandem expression cassettes on the same plas-
mid or as separate cassettes across two separate plas-
mids. Two representative regulators of G0/1, p16 and
p27, were cloned into a mammalian expression plasmid
such that a GFP reporter and the regulator expression
cassettes were arranged in tandem. Cells were transiently
transfected with the tandem cassette plasmid as de-
scribed above and the level of cell cycle arrest compared
to that from cells co-transfected with plasmids that sep-
arately encoded the two expression cassettes. The nega-
tive control consisted of a plasmid encoding DsRed
expression, which is not expected to impact cell cycle ar-
rest. The data shows that for both p16 and p27, the de-
gree of arrest in G0/1 is increased when the expression
cassettes are separated across plasmids relative to when
they are arranged in tandem on a single plasmid (Fig. 2c).
These results indicate that the particular arrangement of
multiple expression cassettes has an important impact
on regulation of the cell cycle, and under the assay con-
ditions used in this study using two cassettes in tandem
is detrimental. Thus, these results indicate that the opti-
mal configuration to engineer switchable cell cycle con-
trollers is to incorporate a single key regulatory node in
U2-OS cells.
Small molecule control of cell cycle arrest through
ribozyme switches
Having identified key regulatory nodes for the arrest of hu-
man cells in G0/1 and G2/M, we next placed the expres-
sion of the identified regulatory proteins under the control
of small molecule-responsive ribozyme switches. Ribozyme
switches responsive to the small molecule theophylline
were inserted into the 3′ UTR of the expression cassette
for the regulatory node, where small molecule dependent
cleavage modulates mRNA degradation and thus transcript
levels of the regulatory node (Fig. 3a) [29]. The activities
for a set of previously described theophylline-responsive
switches (th-A, th-B, th-C) [31, 32] were characterized in
the cell cycle control system. The switch set was chosen to
exhibit a range of ligand-responsiveness as it was not
known a priori which activity ranges would best match
those of the identified regulatory nodes to allow effective
control over the cell cycle. Based on the performance of
these switches in yeast (Additional file 1: Table S2), switch
th-C is expected to have the highest level of leakiness (i.e.,
basal expression in the absence of ligand) and the lowest
level of activation upon addition of ligand, while switch th-
A is expected to have the lowest level of leakiness and the
highest activation. Introducing a second copy of switch th-
C (th-Cx2) is expected to decrease the leakiness and in-
crease the activation compared to the single switch th-C as
described previously [32].
The ribozyme switches and non-switch negative con-
trols (wild-type sTRSV hammerhead ribozyme, OFF con-
trol; mutated sTRSV hammerhead ribozyme, ON control)
were cloned into the expression cassette for the G2/M
regulatory node CCNB1m. The construct was placed
under the control of a CMVTetO2 promoter and encoded
on a plasmid backbone that allowed site-specific stable in-
tegration into U2-OS T-Rex Flp-In cells via the Flp-In sys-
tem. We initially tested the ribozyme switches for control
over G2/M arrest, because our earlier results indicated
that a higher dynamic range is possible from a G2/M con-
trol system since a higher fraction of the population is
available to be arrested relative to G0/1. The assay was
performed on cell lines that expressed the cell cycle con-
trol construct through a single site-specific integration
such that small molecule induced changes in cell cycle
could be more precisely measured. The expression cas-
sette for the regulatory node was placed under Tet-
inducible control to allow stable cell line creation without
interference from the effects of the cell cycle control sys-
tem (i.e., in the absence of doxycycline), which would bias
selection against the desired cell line since cells with the
activated control system would be expected to grow more
slowly. To characterize performance of the integrated con-
structs, the resulting cell lines harboring the cell cycle
controllers were induced with doxycycline and either 0 or
1 mM theophylline (theo) for three days. Cell lines were
then assayed for the percentage of cells in the different
phases of the cell cycle by flow cytometry analysis as pre-
viously described.
The results for the non-switch controls demonstrated
the expected trends (Additional file 1: Figure S5) and the
different switches exhibited activities in line with the yeast
activity data (Additional file 1: Table S2). Specifically, th-C
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was the most leaky switch tested, with 59 % of the cell
population in G2/M in the absence of theophylline com-
pared to the OFF control for which only 37 % of the cell
population was in G2/M (Fig. 3b). While switch th-C ex-
hibits ligand responsiveness in yeast and in mammalian
cells as measured by fluorescent reporters (Additional file
1: Table S2), it is ineffective in the context of the cell cycle
control system and does not increase the percentage of
cells in G2/M with the addition of theophylline. Adding a
second copy of switch th-C (th-C2x) lowers the amount of
leakiness to only 39 % of the cell population in G2/M and
restores ligand responsiveness to the control system, albeit
by a modest amount (i.e., 46 % of the cell population in
G2/M in the presence of theophylline). Switch th-B exhib-
ited less leakiness and a better activation ratio than switch
th-A in the context of the cell cycle control system, which
was different than their relative activities observed in yeast
(Additional file 1: Table S2). Specifically, cells harboring
switch th-B have 42 % of the cell population in G2/M in
the absence of theophylline, compared with 55 % from
cells harboring switch th-A. However, after induction with
theophylline, the cell population in G2/M increases 1.5-
fold in cells harboring switch th-B, compared with 1.3-fold
in cells harboring switch th-A.
We selected the theophylline switch (th-A), which
arrested the largest percentage of the cell population in
the presence of theophylline (up to 73 %), and verified the
underlying mechanism via changes in the levels of the tar-
get protein and transcript as a function of theophylline.
The gene-regulatory activity of switch th-A was verified by
characterizing its activity in the context of an expression
cassette for an mCherry reporter. The switch was cloned
into the 3′ UTR of an mCherry expression cassette, and
the plasmid encoding this construct was transiently trans-
fected into HEK293 cells. The cells were induced with
varying levels of theophylline, and fluorescence was mea-
sured by flow cytometry after three days of growth. The
results indicate that the presence of theophylline increases
the amount of reporter protein expression in a concentra-
tion dependent manner (Fig. 3c). We further verified that
the transcript levels of CCNB1m increased with addition
of theophylline to the cells. The cell lines harboring the
stably integrated OFF control or switch th-A were induced
with doxycycline and either 0 or 1 mM theophylline for
Fig. 3 Small molecule-responsive ribozyme switches control arrest of cells in G2/M. a Schematic of the mechanism by which ribozyme switches
mediate small molecule-dependent transition of cells into a G2/M arrest state, rather than the normal G2/M state, by regulating expression of
CCNB1m. b A set of theophylline-responsive switches and a non-switch control (wild-type sTRSV hammerhead ribozyme; OFF control) were
inserted in the 3′ UTR of CCNB1m, stably integrated into U2-OS T-Rex Flp-In cells, and tested with 0 or 1 mM theophylline (theo) for their ability
to arrest cells in G2/M. c Characterization of gene-regulatory activity of switch th-A measured as reporter protein activity as a function of theophylline
concentration. HEK293 cells were transiently transfected with a plasmid encoding switch th-A in the 3′ UTR of a mCherry reporter and induced with
varying levels of theophylline. Mean fluorescence of the population was measured by flow cytometry. d Characterization of gene-regulatory activity of
switch th-A measured as CCNB1m transcript levels in the presence and absence of theophylline. Cell lines harboring the stably integrated OFF control
and switch th-A in the 3’UTR of the CCNB1m expression cassette were grown in 0 or 1 mM theophylline and CCNB1m transcript levels relative to that
of a housekeeping gene (ACTB) were measured by qRT-PCR. *, p < 0.05, ****, p< 1E-4. Error bars represent standard deviation across biological triplicates
for (b) and duplicates for (c) and (d)
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three days. Total RNA was extracted from the samples
and the levels of the CCNB1m transcript relative to those
of a housekeeping gene (ACTB) were measured by quanti-
tative real-time PCR (qRT-PCR). The results indicate that
for a control system harboring the th-A switch, CCNB1m
mRNA levels increase by 1.5-fold upon addition of theo-
phylline, whereas those from a control system harboring
the OFF control do not change upon the addition of theo-
phylline (Fig. 3d). Taken together, the data support that
the ribozyme switch-based cell cycle control system func-
tions through specific modulation of the levels of the key
regulatory node in response to the cognate ligand.
Inducible and dynamic control of multiple phases of the
cell cycle through ribozyme switches
Having shown that small molecule-responsive ribozyme
switches can be applied to control progression of human
cells through the G2/M to G0/1 transition, we next exam-
ined whether a similar strategy could be used to control
progression through the G0/1 to S transition (Fig. 4a). We
selected p27 as the regulatory node for G0/1 arrest as it
was the most effective of the nodes identified for inducing
cell cycle arrest in G0/1 across multiple experiments. We
further examined the ligand responsiveness and dynamics
of cell cycle controllers based on ribozyme switches with
these cell lines.
To build a cell cycle controller for G0/1, the
theophylline-responsive switch th-A and the non-switch
controls (wild-type sTRSV hammerhead ribozyme, OFF
control; mutated sTRSV hammerhead ribozyme, ON
control) were cloned into the expression cassette for the
G0/1 regulatory node p27. The construct was placed
under the control of a CMVTetO2 promoter and encoded
on a plasmid backbone that allowed site-specific stable in-
tegration into U2-OS T-Rex Flp-In cells via the Flp-In sys-
tem. The resulting U2-OS cell lines harboring the cell
cycle controller for G0/1 (integrated p27-switch con-
troller), the cell cycle controller for G2/M (integrated
CCNB1m-switch controller), or the respective controls
were induced with doxycycline and a range of theophyl-
line concentrations for three days. Cell lines were then
assayed for the percentage of cells in the different
phases of the cell cycle through flow cytometry analysis
as previously described.
Fig. 4 Small molecule responsive ribozyme switches for titratable and dynamic control over cell cycle. a Schematic of the progression through
the phases of cell cycle (grey and white) with the introduction of the synthetic G0/1 cell cycle control system (blue) and synthetic G2/M cell cycle
control system (orange). b Theophylline responsiveness of the G0/1 cell cycle control system (integrated p27-switch controller). Cell lines harboring the
control system or a negative control were induced with a range of theophylline (theo) concentrations and assayed for the percentage of cells in G0/1 via
DNA staining and flow cytometry. c Theophylline responsiveness of the G2/M cell cycle control system (integrated CCNB1m-switch controller). Cell lines
harboring the control system or a negative control were induced with a range of theophylline (theo) concentrations and assayed for the percentage of
cells in G2/M via DNA staining and flow cytometry. d The response of the G0/1 cell cycle control system to changes in theophylline concentration over
time. Cell lines harboring the G0/1 control system (switch th-A) or a negative control (OFF control) were induced with 0 or 1 mM theophylline. After 3 days,
samples were assayed for arrest in G0/1 by flow cytometry (induce) and re-seeded with 0 mM theophylline. After an additional 3 days, samples were
assayed for G0/1 arrest (remove). e The response of the G2/M cell cycle control system to changes in theophylline concentration over time. Cell lines
harboring the G2/M control system (switch th-A) or a negative control (OFF control) were induced with 0 or 1 mM theophylline. After 3 days, samples were
assayed for arrest in G2/M by flow cytometry (induce) and re-seeded with 0 mM theophylline. After an additional 3 days, samples were assayed for G2/M
arrest (remove). *, p< 0.05. Error bars represent standard deviation across triplicates
Wei and Smolke Journal of Biological Engineering  (2015) 9:21 Page 8 of 13
The synthetic G0/1 cell cycle control system responds to
varying theophylline concentrations by increasing the per-
centage of cells in G0/1. Specifically, the G0/1 control sys-
tem begins to respond to inducer concentrations as low as
0.5 mM, exhibits a maximal switching range at around
1 mM, and begins to show some non-specific effects (i.e.,
OFF control statistically deviates from no induction sam-
ple) at 2 mM theophylline (Fig. 4b). When induced with
1 mM theophylline, 77 % of the cells are in G0/1 compared
to 59 % when uninduced, which represents a significant in-
crease (p-value < 0.05). The percentage of cells arrested
in G0/1 by the control system is close to the expected
maximum performance of this system as determined by
the percent of cells in G0/1 in the ON control system
(Additional file 1: Figure S6). Similar to the initial screen
with transient expression of this regulatory node, the inte-
grated p27-switch control system controlled up to 44 % of
the cells that were previously escaping G0/1 arrest. There
is a small amount of leakage in the device as the unin-
duced switch cell line exhibits slightly more cells in G0/1
(only 3 % more) compared to the OFF control, especially
when compared to the cell cycle controllers for G2/M.
While the synthetic G2/M cell cycle control system simi-
larly responds to varying theophylline concentrations there
are quantitative differences in the response properties of
the two control systems. Specifically, the synthetic G2/M
cell cycle control system also exhibits a maximal switching
range at around 1 mM theophylline and non-specific ef-
fects by 2 mM theophylline (Fig. 4c). At the maximal range
of the control system, 73 % of cells are in G2/M compared
to 55 % in the absence of theophylline. Thus, the integrated
CCNB1m-switch device controls 55 % of the cells that
were previously escaping G2/M arrest. This is substantially
more than the control of 24 % of the previously escaped
cells from transient expression of CCNB1m, which may be
explained by fusion tags coupled to the CCNB1m coding
region within the transient expression construct that were
removed in the integration construct. The G2/M cell cycle
control system exhibits a higher leakiness (~15 %) com-
pared to the OFF control, which has ~40 % of cells in G2/
M. Thus, the G2/M control system is 5 times more leaky
than the G0/1 control system. In addition, the G2/M con-
trol system exhibits a greater sensitivity to the inducing lig-
and; near full induction of the system is observed at
0.25 mM theophylline. The observed quantitative differ-
ences in the response properties between the cell cycle
controllers for G0/1 and G2/M are likely due to the differ-
ences in the mechanism of the regulatory nodes.
We next examined the reversibility of the genetic cell
cycle control systems, or their ability to respond to
changes in the concentration of the small molecule in-
ducer. The cell lines harboring the cell cycle controller for
G0/1 (integrated p27-switch controller), the cell cycle con-
troller for G2/M (integrated CCNB1m-switch controller),
and the respective controls were induced with doxycycline
and 0 or 1 mM theophylline with six samples per condi-
tion. After three days of growth, three samples from each
condition were assayed for the percentage of cells in the
different phases of the cell cycle and three samples were
re-seeded in fresh media with doxycycline and no theo-
phylline. After another three days of growth, the latter
samples were assayed for the percentage of cells in the dif-
ferent phases of the cell cycle through flow cytometry ana-
lysis as previously described.
Cells harboring the cell cycle controller for G0/1 ini-
tially displayed an increased percentage of cells in G0/1
(16 % more) and subsequently return to levels of G0/1
identical to samples that were uninduced throughout the
entire experiment (Fig. 4d). Cells harboring the cell cycle
controller for G2/M also initially showed an increased
percentage of cells in G2/M, with 83 % of the total cells
arrested before reverting to a much lower level of 36 %.
However, the percentage of cells in G2/M revert to levels
slightly higher than those from samples that were unin-
duced throughout the entire experiment, which were at
29 % (Fig. 4e). These results indicate that the effects
from the genetic cell cycle control systems are generally
reversible within three days of removal of the inducing
molecule from the cells.
Overall, the results demonstrate that ribozyme switches
can modularly and reversibly arrest human cells in differ-
ent phases of the cell cycle by linking them to the expres-
sion of key regulators of the cell cycle.
Reliability of ribozyme switch-based cell cycle control
systems
One important property of synthetic biological circuits is
their reliability over time, particularly as it relates to com-
plex phenotypes. Thus, we examined the performance of
the cell cycle control systems over time and across experi-
ments by leveraging the stable cell lines generated through
the course of our experiments.
Cell cycle measurements performed on the cell lines
harboring the cell cycle controller for G0/1 (integrated
p27-switch controller), the cell cycle controller for G2/
M (integrated CCNB1m-switch controller), and the re-
spective controls three days after induction with doxy-
cycline and either 0 mM or 1 mM theophylline from
several independent experiments were compared. The
aggregated results show that the cell cycle controller
for G0/1 is highly reliable, with no significant deviation
when comparing performance before and after a freeze-
thaw cycle nor when comparing performance over
3 weeks (Fig. 5a). In contrast, aggregated results for the
cell cycle controller for G2/M show a significant in-
crease in the measured arrest in G2/M over time, with
the difference in the percentage of cells measured to be
in G2/M drifting by at least 4 % (for cell lines harboring
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the OFF control) and up to 20 % (for cell lines harbor-
ing switch th-A) (Fig. 5b). This is especially prominent in
the CCNB1m-th-A cell line which change from ~60 %
cells in G2/M during week one to ~80 % cells in G2/M
during week six in the presence of theophylline and
from ~40 % to 60 % in the absence of theophylline. The
observed drift in percent of cells in G2/M over time
from this cell line may be due to the overexpression of
CCNB1m, which contains mutations that protect it
from the naturally regulated degradation pathway and
thus is quite long lived and likely accumulating in the
cell line over time, ultimately leading to increased sus-
ceptibility to arrest in G2/M. Taken together, the results
indicate that the specific choice of key regulatory node
that is implemented in these genetic control systems
can impact the reliability of control system activity
over time.
Conclusion
Despite the complexity and scale of the endogenous
gene networks that control human cell cycle transitions,
it is possible to identify key regulatory nodes that induce
population level increases in the percentage of cells in a
population that are in the G0/1 phase or the G2/M
phase of the cell cycle. Small molecule-responsive ribo-
zyme switches can be modularly applied to control arrest
of cells in the G0/1 or the G2/M phases of the cell cycle
by controlling the identified key regulators of the cell
cycle. The resulting synthetic cell cycle control systems
dynamically respond to changing levels of the cognate
small molecule inducer. Finally, ribozyme-based control-
lers of the cell cycle can be highly reliable, reproducibly
performing with no significant deviation over the course
of several weeks.
Compared to currently available small molecule inhibi-
tors of the cell cycle or nutrient deprivation methods
[20], a switchable ribozyme gene expression control plat-
form for inducible cell cycle arrest has several advan-
tages. For example, the switches can be programmed to
respond to both exogenous small molecule inputs as
well as endogenous protein inputs [31, 48] by swapping
out the aptamer region of the switch, whereas current
chemical methods are limited to control by exogenous
inputs only. Therefore, proteins serve as generalizable
biological connectors between genetic switches and de-
vices, as well as between the native and synthetic pro-
grams [49–51]. In addition, the rate of development of
new small molecule cell cycle inhibitors is slowing [52].
In contrast, while this first generation of ribozyme cell
cycle controller is less effective (~80 % cells are arrested
in the desired phase), rapid development of new genera-
tions is enabled by the availability of high-throughput
approaches for screening target proteins as well as new
switches [30, 31, 48].
Ribozyme switches are an effective, inducible, and
reversible method of controlling arrest of human cells
in both G0/1 and G2/M. To our knowledge, this is the
first time synthetic RNA devices have been used to
control the mammalian cell cycle. Furthermore, these
cell cycle controllers can be readily adapted to arrest
cells in other phases of the cell cycle, in response to a
variety of different inputs, and to be part of larger
synthetic programs. Thus, RNA devices are a promis-
ing synthetic biology tool that enables the engineer-
ing of sophisticated multi-output cellular programs in
higher organisms.
Fig. 5 Reliability of cell cycle control systems over time. a Performance
of the cell cycle controller for G0/1 (integrated p27-switch controller)
over time. Cells harboring the G0/1 cell cycle controller (p27 switch
th-A) or a negative control (p27 OFF control) were induced with 0 or
1 mM theophylline (theo) and the percentage of the cell population in
G0/1 was measured via DNA staining and flow cytometry after creation
of the cell lines (left of hash marks) and at 1 and 3 weeks after cell lines
were frozen and revived (right of hash marks). b Performance of the
cell cycle controller for G2/M (integrated CCNB1m-switch controller)
over time. Cells harboring the G2/M cell cycle controller (CCNB1m
switch th-A) or a negative control (CCNB1m OFF control) were induced
with 0 or 1 mM theophylline and the percentage of the cell population
in G2/M was measured via DNA staining and flow cytometry at 1, 2, 3
and 6 weeks after creation of the cell lines
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Methods
Plasmid construction
Plasmids were constructed using standard molecular biol-
ogy techniques [53]. Oligonucleotides were synthesized by
Integrated DNA Technologies or the Stanford Protein and
Nucleic Acid Facility (PAN, Stanford, CA) and constructs
were sequence verified (Laragen, Inc., Culver City, CA or
Elim Biopharmaceuticals, Inc., Hayward, CA). Cloning en-
zymes, including restriction enzymes and T4 DNA ligase,
were obtained from New England Biolabs (Ipswich, MA),
and DNA polymerases were obtained from Stratagene
(Agilent Technologies, Santa Clara, CA). Plasmids were
prepared from Escherichia coli using Econospin col-
umns (Epoch Life Science, Missouri City, TX) or Pure-
Yield plasmid miniprep system (Promega Corporation,
Madison, WI) according to manufacturer’s instructions.
For a detailed description of plasmid construction
methods see Additional file 1: Text S1 and Figure S7.
Lists of plasmids and ribozyme switch sequences are
provided in Additional file 1: Tables S5 and S6.
Mammalian cell culture
U2-OS cells (a generous gift from the Katrin Chua Labora-
tory, Stanford, CA), HeLa cells (a generous gift from the
James Chen Laboratory, Stanford, CA), and HEK293 were
cultured in D-MEM media with 10 % FBS and passaged
regularly. Parental U2-OS T-Rex Flp-In cells (a generous
gift from the Pamela Silver Laboratory [14]) were main-
tained in DMEM supplemented with 10 % FBS, 0.1 mg/ml
zeocin (Life Technologies, Carlsbad, CA), and 2.5 μg/ml
blasticidin (Life Technologies). All cells were grown at
37 °C, 5 % CO2, and 80 % humidity. Stable transfection of
U2-OS T-REx FlpIn cell lines was performed using the
Flp-In recombinase system (Life Technologies) accord-
ing to the manufacturer’s instructions to generate iso-
genic stable cell lines. Stable integrants were selected
using 0.2 mg/ml hygromycin B (Life Technologies),
whereas stable cell lines were maintained in 0.1 mg/ml
hygromycin B and 2.5 μg/ml blasticidin. For a list of
cell lines, see Additional file 1: Table S3.
qRT-PCR assays
Stable U2-OS cell lines of interest were seeded at 0.02 ×
10^6 cells/ml in 6 cm plates with 25 ng/ml doxycycline
and 0 or 1 mM theophylline (Sigma-Aldrich, St. Louis,
MO) in duplicate. 72 h after seeding, supernatant along
with trypsinized cells were collected by spinning at 300 g
for 5 min. Samples were washed once with PBS in 1.5 ml
microfuge tubes and used PBS was aspirated. Cell pellets
were flash frozen in liquid nitrogen and stored at −80 °C.
RNA extraction was performed using GenElute™ Mam-
malian Total RNA Miniprep Kit (Sigma-Aldrich) according
to the manufacturer’s instructions. Reverse transcription
with primer 26_ACTB_REV or B1m-4_rv (Additional file
1: Table S4) was performed using SuperScript III reverse
transcriptase (Life Technologies) according the manufac-
turer’s instructions using at least 200 ng of total RNA.
qPCR was performed using EvaGreen master mix
(Biotium, Hayward, CA) using 15 ng of template and
0.5 μM each of primers 25_ACTB_FWD and 26_ACT-
B_REV to measure the housekeeping control (ACTB)
and primers B1m-4_fw and B1m-4_rv to measure
CCNB1m transcript levels (Additional file 1: Table S4)
according to the manufacturer’s instructions on a Bio-
Rad iCycler with a cycle of 95 °C (15 s), 55 °C (15 s),
and 72 °C (30 s) run at least 45 cycles. Relative expres-
sion was calculated by the ΔCT method according to
the manufacturer’s manual.
Fluorescence reporter assays
HEK293 cells were seeded at 0.16 × 10^6 cells/ml in 24-
well plates. 24 h after seeding, cells were transfected with
FuGENE HD (Promega) according the manufacturer’s in-
structions using 500 ng total plasmid and induced with 0,
2, or 5 mM theophylline. 72 h after transfection, at least
5000 cells were collected and run on a MACSQuant VYB
(Miltenyi Biotec, Bergisch Gladbach, Germany) and
mCherry was excited by a 561 nm laser and detected by a
615/20 band-pass filter. The data was gated for live cells
using side scatter vs. forward scatter and the geometric
mean fluorescence of the mCherry signal was deter-
mined using FlowJo software (Tree Star, Ashland, OR).
The average and standard deviation across biological
duplicates are plotted.
Stable cell line cell cycle assays
Stable U2-OS cell lines of interest were seeded at 0.01–
0.02 × 10^6 cells/ml in 6 cm plates with 25 ng/ml doxy-
cycline and 0 to 4 mM theophylline (Sigma). 72 h after
seeding, DNA content was measured following propidium
iodide (PI) staining according to previously described pro-
tocols modified to use 100 % methanol for >10 min instead
of 70 % ethanol and a final concentration of 20 μg/ml PI
rather than 10 μg/ml [54]. At least 10,000 cells from sam-
ples were run on a MACSQuant VYB (Miltenyi Biotec)
and PI staining was excited by a 561 nm laser and detected
by a 615/20 band-pass filter output linear. The data was
gated to exclude debris using side scatter vs. forward
scatter, then for singlets using the height of forward
scatter vs. the area of the forward scatter signal. Next,
histograms of cell frequency vs. DNA content were
gated manually for cells in G0/1, S, and G2/M phase
using FlowJo software (Tree Star, Ashland, OR) with
the leftmost peak representing 1n chromosome stain-
ing, or cells in G0/1, the rightmost peak representing
2n chromosome staining, or cells in G2/M, and inter-
mediate staining representing cells in S, as described in
Pozarowski et al. (Additional file 1: Figure S1, S2).
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For reversibility experiments, 72 h after initial seeding,
the cell cycle assay was performed on samples as de-
scribed above and samples were re-seeded to 0.01–0.02 ×
10^6 cells/ml in 6 cm dishes in fresh media with 25 ng/ml
doxycycline and no theophylline. After an additional 72 h
of growth, DNA content was measured with PI staining
and an analysis of the percentage of cells in G0/1, S, and
G2/M was performed as described above.
Transient cell cycle assays
For transient assays, U2-OS cells were seeded at 0.02 ×
10^6 cells/ml in 6 cm plates. 24 h after seeding, cells were
transfected with FuGENE HD (Promega) according to the
manufacturer’s instructions using 4.5 μg total plasmid.
During our initial protocol optimization, the total amount
of DNA transfected (i.e., transfection marker plasmid and
regulatory protein plasmid) was determined by the
amount that produced the best transfection efficiency in
U2-OS cells using FuGENE HD in 6-well plates while
maintaining a low enough toxicity such that >10,000 GFP
positive cells per sample could be quantified in the flow
cytometry assay. At this upper limit of total transfected
DNA (i.e., 4.5 μg) the ratio of the amount of transfection
marker plasmid relative to the amount of plasmid
encoding the protein of interest was then optimized to
maximize the amount of protein of interest plasmid that
was added while preserving high enough levels of GFP
signal at the time of assaying the cells to allow quantifi-
cation of >10,000 GFP positive cells per sample. For 2
plasmid co-transfections, 1.125–1.5 μg of pCS2622 and
3–3.375 μg of the second plasmid were used. For
greater than 2 plasmid co-transfections, equal mass of
each plasmid was added.
Seventy two hours after transfection, DNA staining
was performed as described above modified to replace
methanol permeabilization. Specifically, cells were fixed
using 0.5 % formaldehyde for 20 min at 4 °C, washed
once with PBS, then permeabilized with 70 % ethanol
for at least 2 h. During the initial protocol optimization,
it was determined that 72 h after transfection was a rea-
sonable time to assay for cell cycle changes because at
this time point the cells had sufficiently recovered from
transfection, the density of cells in the dishes was high
enough that >10,000 GFP positive cells per sample could
be reliably quantified, and the cell density was not so
high that contact inhibition of growth would begin to
mask cell cycle arrest induced by the overexpression of
the potential regulatory node proteins being screened. In
addition to the data processing described above, after gat-
ing for singlets, GFP (excited by a 488 nm laser and de-
tected by a 525/50 band-pass filter) signal is used to gate
for transfected cells before analysis of DNA staining in the
GFP positive subpopulation (Additional file 1: Figure S1).
Note that the GFP reporter was membrane-tagged to en-
sure GFP signal is preserved after fixation step [55].
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